Peptide CDMO (Pharmaceutical) Market Forecast by Scale Method Applications and Regional Opportunities 2025-2034

The Peptide CDMO (Pharmaceutical) Market Size is valued at 2.5 Bn in 2024 and is predicted to reach 6.6 Bn by the year 2034 at a 10.4 % CAGR during the forecast period for 2025-2034.

Peptide Contract Development and Manufacturing Organizations (CDMOs) are specialized entities focused on the production of peptides, which are short sequences of amino acids connected by peptide bonds. Their operations require meticulous assembly of amino acids in a precise sequence while maintaining the integrity of functional groups to ensure the desired structural and biological properties. Peptide synthesis is accomplished through several approaches, including solid-phase synthesis, solution-phase synthesis, and recombinant DNA technology.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1202

The rising incidence of chronic diseases has led to increased demand for advanced therapeutic solutions. Peptide-based therapies present significant advantages, such as high target specificity, the ability to modulate key biochemical pathways, and the potential for reduced dosing.

As a result, the adoption of peptide therapeutics is growing across diverse therapeutic segments, including oncology, cardiovascular disease, and diabetes care. CDMOs are instrumental in meeting this demand by offering specialized expertise in both the development and large-scale manufacturing of peptide-based pharmaceutical products.

List of Prominent Players in the Peptide CDMO (Pharmaceutical) Market:

• AmbioPharm
• Auspep
• Bachem
• BCN Peptide
• CPC Scientific
• CBL- Chemical and Biopharmaceutical Laboratories
• Creative Peptides
• Chinese Peptide
• CSBio
• Corden Pharma
• PolyPeptide
• Hybio Pharmaceutical
• Peptide Institute
• Pepscan
• Almac
• Vivitide
• CreoSalus Inc
• ScinoPharm
• Senn Chemicals
• Wuxi AppTec
• Olon
• Belyntic
• Ferring Pharma
• Numaferm
• Hybio Pharmaceutical
• Provepharm Life Solutions
• Enzene Biosciences
• Ardena Holding
• Stelis Biopharma
• Piramal Pharma
• Space Peptides Pharmaceutical

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics

Drivers:

The global peptide CDMO (pharmaceutical) services market is witnessing strong growth, fueled by the expanding therapeutic applications of peptides, ongoing technological innovations in healthcare, and heightened interest from pharmaceutical companies in peptide-based drug development. The increasing prevalence of chronic diseases, coupled with growing consumer focus on health and wellness, further supports market expansion.

To improve operational efficiency and scalability, pharmaceutical firms are increasingly engaging in strategic partnerships to enhance development, engineering, and manufacturing capabilities for peptide production. These combined factors are anticipated to drive sustained growth in the peptide CDMO market throughout the forecast period.

Challenges:

Despite promising growth prospects, the market faces challenges associated with the complexity and high costs of peptide manufacturing. Peptide synthesis requires specialized equipment and technical expertise, as peptides are inherently more difficult to produce than conventional small-molecule drugs.

The rising demand for peptide therapeutics emphasizes the need for efficient and scalable production processes. High manufacturing costs may restrict access to peptide-based treatments in certain regions.

Additionally, delivery mechanisms, including cell-penetrating peptides, often transport only a portion of the administered dose to target cells, with the remainder susceptible to metabolism or degradation, potentially reducing therapeutic effectiveness. Disruptions from the COVID-19 pandemic—such as global supply chain interruptions, workforce shortages, and increased product demand—have highlighted the need for careful management of production capacity and resources.

Regional Trends:

North America is expected to hold a significant revenue share of the global peptide CDMO market, driven by advances in biosynthesis technologies and the growth of the chemical and pharmaceutical sectors. Ongoing research and development, particularly in genomics and personalized medicine, is further stimulating demand for specialized CDMO services.

Europe also represents a critical market, supported by a substantial patient population, increasing healthcare expenditures, and strong engagement from multinational pharmaceutical companies seeking opportunities in the peptide CDMO space.

 Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1202

Recent Developments:

• In March 2024, Ferring Pharmaceuticals and SK Pharmateco reached a partnership to increase the industrial production capability of Adstiladrin (nadofaragene firadenovec-vncg), the medication used in Ferring’s intravesical genetic therapy.
• In August 2024, AmbioPharma revealed its selection of Brian Gregg, a business veteran, as its new CEO. Mr. Gregg takes over from Tim Nieters, who is leaving the business after seven seasons and has a long history of expertise in the peptide CDMO sector.

Segmentation of Peptide CDMO (Pharmaceutical) Market-

By Scale of Operation-

• Preclinical
• Clinical
• Commercial

By Method Used-

• Chemical Synthesis Method
• Non-Chemical Synthesis Method

By Applications-

• Peptide Supplements
• Peptide Vaccines
• Peptides as Radio-theranostic Agents
• Cell-penetrating Peptides (CPPs)
• Affinity Ligands
• Protein Mimics

By Synthesis Types-

• LPPS
• SPPS
• Mixed Phase

By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of the Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Tags: Peptide CDMO (Pharmaceutical) Market